Page 894 - Read Online

Page 12 of 14 Cullen et al. Hepatoma Res 2020;6:76 I http://dx.doi.org/10.20517/2394-5079.2020.69

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in
GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
2. Berumen J, Hemming A. Liver transplantation for hepatocellular carcinoma. Abdom Radiol (NY) 2018;43:185-92.
3. Proneth A, Zeman F, Schlitt HJ, Schnitzbauer AA. Is resection or transplantation the ideal treatment in patients with hepatocellular
carcinoma in cirrhosis if both are possible? A systematic review and metaanalysis. Ann Surg Oncol 2014;21:3096-107.
4. Mulligan DC. The ongoing quest to find the appropriate patients to transplant with hepatocellular carcinoma: Milan to san Francisco to
Toronto and beyond. Hepatology 2016;64:1853-5.
5. Sapisochin G, Goldaracena N, Laurence JM, et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular
carcinoma: a prospective validation study. Hepatology 2016;64:2077-88.
6. Raia S, Nery JR, Mies S. Liver transplantation from live donors. Lancet 1989;2:497.
7. Wong TCL, Ng KKC, Fung JYY, et al. Long-term survival outcome between living donor and deceased donor liver transplant
for hepatocellular carcinoma: intention-to-treat and propensity score matching analyses. Ann Surg Oncol 2019;26:1454-62.
8. Cheung TTT, Kwok PCH, Chan S, et al. Hong Kong consensus statements for the management of unresectable hepatocellular carcinoma.
Liver Cancer 2018;7:40-54.
9. de Freitas LBR, Longo L, Santos D, Grivicich I, Álvares-da-Silva MR. Hepatocellular carcinoma staging systems: Hong Kong liver
cancer vs Barcelona clinic liver cancer in a Western population. World J Hepatol 2019;11:678-88.
10. De Souza Martins Fernandes E, Rodrigues PD, Álvares-da-Silva MR, et al. Treatment strategies for locally advanced hepatocellular
carcinoma. Transl Gastroenterol Hepatol 2019;4:12.
11. Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and
insights. Hepatobiliary Surg Nutr 2020;9:452-63.
12. Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991;214:221-
9.
13. Bigourdan JM, Jaeck D, Meyer N, et al. Small hepatocellular carcinoma in Child A cirrhotic patients: hepatic resection versus
transplantation. Liver Transpl 2003;9:513-20.
14. Bhangui P, Vibert E, Majno P, et al. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased
donor transplantation. Hepatology 2011;53:1570-9.
15. Azoulay D, Audureau E, Bhangui P, et al. Living or brain-dead donor liver transplantation for hepatocellular carcinoma. Ann Surg
2017;266:1035-44.
16. Goldaracena N, Gorgen A, Doyle A, et al. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased
survival vs. deceased donation. J Hepatol 2019;70:666-73.
17. Xiao GQ, Song JL, Shen S, Yang JY, Yan LN. Living donor liver transplantation does not increase tumor recurrence of hepatocellular
carcinoma compared to deceased donor transplantation. World J Gastroenterol 2014;20:10953-9.
18. Fisher RA, Kulik LM, Freise CE, et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver
transplantation. Am J Transplant 2007;7:1601-8.
19. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with
cirrhosis. N Engl J Med 1996;334:693-9.
20. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not
adversely impact survival. Hepatology 2001;33:1394-403.
21. Lee SG, Hwang S, Moon DB, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one
large-volume center. Liver Transpl 2008;14:935-45.
22. Cillo U, Giuliani T, Polacco M, et al. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver
transplantation. World J Gastroenterol 2016;22:232-52.
23. Lee SD, Lee B, Kim SH, et al. Proposal of new expanded selection criteria using total tumor size and (18)F-fluorodeoxyglucose - positron
emission tomography/computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma: The National
Cancer Center Korea criteria. World J Transplant 2016;6:411-22.
24. Uchiyama H, Itoh S, Yoshizumi T, et al. Living donor liver transplantation for hepatocellular carcinoma: results of prospective patient
selection by Kyushu University Criteria in 7 years. HPB (Oxford) 2017;19:1082-90.
25. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with
unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.
26. Wang JC, Xia AL, Xu Y, Lu XJ. Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis. J Cell
Physiol 2019;234:1062-70.